Use PET and MRI Imaging Methods Early to Reduce Drug Development Risk
About this webinar
Decisions made early in the drug development process from preclinical through Phase IIa can disproportionately impact later development as costs increase with each phase.
Timely information quantifying drug distribution to tissues of interest, the relationship between plasma concentration and target occupancy and pharmacodynamic effects of drugs engaging the target can significantly reduce the costs, complexity and failure rate of later-stage clinical trials. This webinar explores how PET and MRI imaging methods can provide biologically meaningful outcome measures that support earlier drug development decisions.
Early evaluation of potential imaging biomarkers and their integration into the development pipeline can provide substantial benefits to a portfolio of compounds under development. The featured speaker will discuss the role of different imaging methods used to evaluate biologically meaningful outcome measures across the drug development pipeline, including the time and resource requirements needed to integrate these methods effectively into development programs.
This webinar will focus on CNS drug development as one of the more established therapeutic areas to employ imaging methods, while applying principles that are applicable across the therapeutic spectrum.
Register for this webinar to learn how imaging methods can support confident go/no-go decision-making and optimize drug development planning.
Who should attend
- Early Phase Drug Developers
- Translational Scientists
- Imaging Scientists
- Image Analysis and Quantitative Imaging Specialists
- Pharmacology and Biodistribution Scientists
- Preclinical Research Directors and Scientific leaders
- Biotech and pharmaceutical professionals utilizing PET, SPECT, MRI or multimodal imaging
What you will learn
- Understand the principles of imaging methodologies
- Understand the role of various imaging outcome measures in the drug development decision-making process
- Explore the role of various imaging studies in the drug development process
Featured Speakers
Eugenii A. (Ilan) Rabiner, BSc (Hons), MBBCh, FCPsych SA
Ilan Rabiner is a Psychiatrist, Psychopharmacologist and Imaging Scientist with 30 years of experience in the application of PET and MRI to the investigation of human normo- and patho-physiology and the application of these techniques to support drug development. He held leading posts in academia and the pharmaceutical industry, has over 200 peer-reviewed publications and an h-index of 65.
Partner for this event
Perceptive Discovery
Perceptive Discovery bridges the gap between preclinical insights and early clinical success, providing the expertise and high-quality data needed to advance innovation with confidence. With deep expertise in advanced imaging, radiochemistry, and translational science, we specialize in supporting drug development programs across CNS, oncology, and radioligand therapy. Our integrated approach combines rigorous scientific analysis, state-of-the-art imaging platforms, and multidisciplinary expertise to deliver data that drives smarter decisions, reduces risk, and accelerates timelines from preclinical to first-in-human studies.